UNIVERSITY OF NORTH CAROLINA HOSPITALS

The UNC Lineberger Comprehensive Cancer Center received $28 million from ARPA-H to develop EVOLVE, an innovative clinical trial that adapts metastatic breast cancer treatment in real-time based on tumor changes.

Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment.

CAR T-cell therapy and bispecific antibodies have transformed hematologic malignancy treatment, offering new hope beyond traditional chemotherapy and targeted drugs.

AYA cancer programs address the unique challenges faced by adolescents and young adults (ages 15-39) diagnosed with cancer, offering tailored support.

• Ifinatamab deruxtecan (I-DXd) demonstrated promising activity in patients with extensive-stage small cell lung cancer (ES-SCLC) at the World Congress on Lung Cancer. • The antibody-drug conjugate (ADC) I-DXd showed a dose-response relationship, with higher doses yielding improved overall response rates in ES-SCLC. • Combination strategies involving ADCs like I-DXd with immunotherapy are being explored due to the potential for immunogenic cell death induction. • Protein engineering advancements are enabling the development of targeted therapies with improved clinical responses in lung cancer.

The addition of Versamune HPV (PDS0101) to pembrolizumab demonstrated robust and durable responses in first-line treatment for HPV16-positive recurrent or metastatic HNSCC.